News

Video

Frontline Therapy for Renal Cell Carcinoma: Choosing the Right Regimen

Author(s):

Ulka Vaishampayan, MD,Alan Tan, MD

Oncologists discuss the selection of the optimal frontline therapy for renal cell carcinoma, considering factors like response rates, progression, quality of life, and long-term results.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
Shannon N. Westin, MD, MPH, FACOG, director, Early Drug Development, clinical medical director, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, codirector, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center
Sairah Ahmed, M.D
Brandon G. Smaglo, MD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
Neeta Somaiah, MD
Howard Colman, MD, PhD, Jan M. Huntsman Presidential Professor, Department of Neurosurgery, member, Brain Tumor Research Team, and leader, Center for Neurologic Cancers, Huntsman Cancer Institute, University of Utah
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the potential for the use of oral HMAs in MDS.
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the implications of the FDA approval of imetelstat for transfusion-dependent anemia in MDS.
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss other potential roles for luspatercept in MDS and beyond.
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss long-term transfusion independence data for luspatercept in MDS.
Related Content
Brandon G. Smaglo, MD, FACP, on pancreatic cancer
March 4th 2025

Toxicity, Sequencing Considerations Are Key for Frontline Chemotherapy Selection in Metastatic Pancreatic Cancer

Mark B. Geyer, MD, Adolescent and Young Adult Program leader, Adult Lymphoblastic Leukemia Program leader, Leukemia Service, chair, Quality Assessment, Cellular Therapy Service, Memorial Sloan Kettering Cancer Center; Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
February 10th 2025

Ponatinib-Based Regimens Strengthen the Ph+ ALL Treatment Paradigm: With Mark B. Geyer, MD, and Elias Jabbour, MD

Kevin T. Nead, MD, MPhil
February 26th 2025

Cardio-Oncology Investigations Begin to Uncover More Links Between CVD and Breast Cancer

Elias Jabbour, MD, a professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center
February 3rd 2025

Olverembatinib Research Signals a New Era of CP-CML Management: With Elias Jabbour, MD

Anna Parks, MD
February 24th 2025

Anna Parks Receives American Society of Hematology Junior Faculty Scholar Award

Funda Meric-Bernstam, MD
February 21st 2025

Pan-Tumor Approvals Stress the Need for Harmonized Testing and Reporting Strategies